kidney disease hospital WhatsApp

FSGS

Make an Appointment

- Call us:

Viber or Whatsapp:008613463017175
Skype:renaldiseases

- Email us:

renal-disease@hotmail.com

- Online Consultation

Patient Story

kidney disease patient
Home > Understanding Kidney Disease > Kidney Diseases > FSGS > FSGS Treatment >

New Medicine for FSGS

2018-11-28 00:16| Font Size A A A

New Medicine for FSGS

Recently, Howard Trachtman's research team at New York university published a study in the Journal of the American Society of Nephrology, a medical journal of nephrology, that Sparsentan, an antihypertensive drug, can effectively treat focal segmental glomerulosclerosis (FSGS), which is a major advance in the field of nephropathy.

How is the effect of Sparsentan for FSGS patients?

Dr. Howard Trachtman of New York university, said the trial, which involved 109 FSGS patients, confirmed that Sparsentan is more effective than irbesartan and could be the first drug in the world to treat FSGS.

In figure A on the left, under the gray bar is -18.5, representing an 18.5% reduction in urinary protein with treatment of irbesartan; Under the black column is -44.6, representing a 44.6 percent decrease in urinary protein with treatment of Sparsentan.

In figure B on the right, the dose was increased, and it can be seen that Sparsentan decreased the urinary protein by 47.4%.

Patients with FSGS often use hormones and immunosuppressants, but the effect is not very well. And antihypertensive drugs such as irbesartan become the mainstay of reducing urine protein. Clearly, Sparsentan is more effective, which reduced urinary protein by nearly half.

Significance of Sparsentan

Similar to irbesartan, it can also be used as a blood pressure medication, both of which can inhibit angiotensin ii.

In addition, Sparsentan blocks endothelin, which is more powerful than any other drug. The drug was granted orphan drug status last year by the U.S. food and drug administration and the European commission to treat FSGS.

This is the result of phase 2 trial. After the success of phase 3 trial, the drug can be applied for the market, and our first-line clinical treatment effect will be improved to a higher level.

Proteinuria affects the prognosis of FSGS, because it can speed up glomerulosclerosis. If you want to have a prognosis, you should take treatment as early as possible to bring it under control. Hope the above drugs can help you.

Disclaimer: the above information is for educational purposes. For specific treatment suggestions, please consult a physician.

Leave a question or comment and we will try to attend to you shortly. Free medical answers from Professionals!
Please leave your email / whatsapp / phone number below and Disease Description , our doctor will contact you in time. so that our doctor give the correspending help!

Name:
Age:
Gender:
Country:
Email:
Phone:
Disease:
url: